HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity
作者:Denis R. St. Laurent、Michael H. Serrano-Wu、Makonen Belema、Min Ding、Hua Fang、Min Gao、Jason T. Goodrich、Rudolph G. Krause、Julie A. Lemm、Mengping Liu、Omar D. Lopez、Van N. Nguyen、Peter T. Nower、Donald R. O’Boyle、Bradley C. Pearce、Jeffrey L. Romine、Lourdes Valera、Jin-Hua Sun、Ying-Kai Wang、Fukang Yang、Xuejie Yang、Nicholas A. Meanwell、Lawrence B. Snyder
DOI:10.1021/jm301796k
日期:2014.3.13
A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging from an examination of the prolinamide cap region revealed 11 to be a selective HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons. Additional structural refinements resulted in the identification of 30 as a potent, dual G-1a/1b HCV NS5A inhibitor.